Compare ARTW & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTW | BRTX |
|---|---|---|
| Founded | 1956 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | ARTW | BRTX |
|---|---|---|
| Price | $2.48 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.4K | ★ 25.1K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,079,949.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | $6.33 | ★ N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $1.43 | $0.98 |
| 52 Week High | $4.71 | $2.55 |
| Indicator | ARTW | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 47.10 |
| Support Level | $2.36 | $1.10 |
| Resistance Level | $2.45 | $1.24 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 78.57 | 28.96 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.